Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
212 people get ENZ articles and Market Currents by email alert.
Get email alerts on ENZ »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Enzo and NIH File Patent Application for Therapies, Diagnosis, and Prognosis for Autoimmune DiseasesBusiness Wire (May 7, 2013)
-
-
-
-
Business Wire (Mar 12, 2013)
-
Business Wire (Mar 8, 2013)
-
Business Wire (Dec 10, 2012)
-
Business Wire (Dec 6, 2012)
-
Business Wire (Nov 29, 2012)
-
Business Wire (Nov 13, 2012)
-
Business Wire (Nov 12, 2012)
-
Business Wire (Nov 9, 2012)
-
Business Wire (Nov 2, 2012)
-
Business Wire (Oct 12, 2012)
-
Business Wire (Jun 11, 2012)
-
-
Business Wire (Jun 6, 2012)
-
-
N.Y. Approval Of ColonSentry Opens Door For GeneNews And EnzoLen Zehr • Fri, Mar 2, 2012 -
Investors Should Wait Out Quest And LabCorpPaul Nouri • Thu, Feb 16, 2012
-
-
6 Small-Cap Stocks With Bullish Options Sentiment Ahead of EarningsKapitall • Thu, Oct 7, 2010
-
-
Three Top and Bottom Market Sectors for This WeekJ Clinton Hill • Sun, Jun 21, 2009 -
-
Biotech Day in Review: Glaxo Gets Approval for TykerbCentient Biotech Investor • Wed, Mar 14, 2007
-
Enzo Biochem, Inc. F2Q09 (Qtr End 01/31/09) Earnings Call TranscriptSat, Mar 21, 2009
-
Enzo Biochem, Inc. F3Q08 (Qtr End 4/30/08) Earnings Call TranscriptTue, Jun 10, 2008
-
Enzo Biochem F1Q08 (Qtr End 10/31/07) Conference Call TranscriptTue, Dec 11, 2007
-
Enzo Biochem F4Q07 (Qtr End 7/31/07) Earnings Call TranscriptTue, Oct 16, 2007
-
Enzo and NIH File Patent Application for Therapies, Diagnosis, and Prognosis for Autoimmune DiseasesBusiness Wire (May 7, 2013)
-
Business Wire (Mar 12, 2013)
-
Business Wire (Mar 8, 2013)
-
Business Wire (Dec 10, 2012)
-
Business Wire (Dec 6, 2012)
-
at CNBC.com (Nov 30, 2012)
-
Business Wire (Nov 29, 2012)
-
Business Wire (Nov 13, 2012)
-
Business Wire (Nov 12, 2012)
-
Business Wire (Nov 9, 2012)
-
Business Wire (Nov 2, 2012)
-
Business Wire (Oct 12, 2012)
-
Business Wire (Jun 11, 2012)
-
at MarketWatch.com (Jun 11, 2012)
-
Business Wire (Jun 6, 2012)
-
Business Wire (Mar 27, 2012)
-
Business Wire (Mar 20, 2012)
ENZ vs. ETF Alternatives
Company Description
Currently, there's no company description for ENZ.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Monday, November 5, 2012, 12:45 PM
Midday top 10 gainers: NVGN +50%. ICAD +43%. NTE +36%. HMNY +19%. BMRN +30%. OPTT +25%. VRNG +23%. EQU +15%. BEE +13%. BITA +12%.
Top 10 Losers: EBIX -22%. HGSH -19%. RDN -14%. PCYC -12%. MEAD -15%. VTUS -10%. PKBK -10%. COCO -9%. PGRX -9%. ENZ -9%. 1 Comment [On the Move] - Tuesday, December 13, 2011, 2:03 PM Enzo Biochem (ENZ -9.3%) takes a hit after its FQ1 misses across the board. Net losses widened Y/Y, as royalty payments declined and operating expenses jumped 11% due to higher SG&A expenses. Comment! [Healthcare, On the Move]
-
- View all 2 replies
-
Susan Kilburg: SVNT classic setup. Two weeks of consolidation; volume drying up and a bear raid this morning created a perfect buying opportunity.
-
-
- View all 0 replies
-
The Wall Street Transcript
Monetizing Price Discrepancies in Health Care Equities; Analyst Discusses $CYH, $ENZ, $TRIB - http://su.pr/2g4QwS - View all 0 replies
-
Jim Van Meerten
ENZ - Enzo Biochem-40% Barchart.com short term technical sell signal- lost 14.48% in the last month-Relative Strength Index 41.28% & falling - View all 0 replies
-
Jim Van Meerten
ENZ - Enzo Biochem- 96% Barchart technical buy signal - 16 new highs and up 25.60% last month- Relative Strength Index 68.30% and rising - View all 0 replies
LATEST REPLIES
-
- View all 2 replies
-
Susan Kilburg: SVNT classic setup. Two weeks of consolidation; volume drying up and a bear raid this morning created a perfect buying opportunity.
-